This was on the Ample investor bulletin board by Professor Higgins...thought it was a useful summary of what 2004 could hold...
'Been in this share for 4 years now and feel that 2004 is the year for this share to break out. Info I am looking for is:
1) Increasing OPTI sales currently recorded as US$1m for the first month (APRIL 2003)- this will give an important revenue stream for development of the main OMH product - BV/Integrated Vaginal Infection Product.
2) News of their marketing partner for the launch of the above product in 2005.
3) Details when the last and final FDA submission is due.
4) Confirmation that there will be little need to approach existing investors for further funds - already lessoned due to recent initiatives and OPTI sales.
5) Some indication whether OMh will remain in the AIM market or look to create a listing in the USA - or of course both.
6) News of new inititives to increase revenue in the short term similar to the OPTI sales....due 2004.
7) Roche's view and further involvement
just to name a few...
Got a good feeling on this share and I will be trading long after the 30th Jan as my personal view is that this could follow the Antisoma (ASM) track...shot forward from 12p to 30p and then onto 40p within a few weeks of marketing details.
Will always respect short traders...you take your chances but sometimes it is time to back a share to the end game....that is the only way you earn substantial wealth.
Having followed this for some time the past performance of these type of shares rarely gives a true prediction of future performance. The questions and details I have listed above are the ones likely to drive this share.
Osmetech stock quotes
Osmetech stock charts
Follow this thread
